Arthur E. Frankel

A STING-activating nanovaccine for cancer immunotherapy

Min Luo, Hua Wang, Zhaohui Wang et al. · Nature Nanotechnology · 2017 · 859 citations · Full text

Nanomedicine, Sting-activating Nanovaccine, Immunology +5

Metagenomic Shotgun Sequencing and Unbiased Metabolomic Profiling Identify Specific Human Gut Microbiota and Metabolites Associated with Immune Checkpoint Therapy Efficacy in Melanoma Patients

Arthur E. Frankel, Laura Coughlin, Jiwoong Kim et al. · Neoplasia · 2017 · 667 citations · Full text

Specific Gut Microbiota, Dysbiosis, Immunology +22

First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors

Gerald S. Falchook, Jeffrey R. Infante, Hendrik‐Tobias Arkenau et al. · EClinicalMedicine · 2021 · 250 citations · Full text

CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies

Ugo Testa, Elvira Pelosi, Arthur E. Frankel · Biomarker Research · 2014 · 249 citations · Full text

Hematological Malignancy, Medicine, Fusion Molecule +15

HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma

Kevin D. Courtney, Yuanqing Ma, Alberto Diaz de Leon et al. · Clinical Cancer Research · 2019 · 177 citations · Full text